儿童超声造影:照亮美国寻求监管批准之路
本文回顾了儿童超声造影(包括静脉注射超声造影和腔内途径的排泄性尿路超声造影)在欧洲等地长期被接受后,美国FDA于2016年首次批准Lumason用于儿童局灶性肝病灶评估,随后批准其用于膀胱输尿管反流评估及2019年用于儿童超声心动图检查的历程。文章描述了国际超声造影学会和儿科放射学会推动批准的过程,并指出理解该批准历史有助于指导儿童人群超说明书应用超声造影剂的实践。
要点
- 2016年FDA首次批准Lumason静脉注射用于儿童局灶性肝病灶评估,此前无前瞻性儿童临床试验。
- FDA随后基于文献批准Lumason经膀胱内给药评估儿童已知或疑似膀胱输尿管反流。
- 2019年FDA基于涉及2个中心共12名受试者的临床试验批准Lumason用于儿童超声心动图检查。
核心结论
- 儿童超声造影在美获得FDA批准历经十余年,理解这一批准历史将影响超声造影剂的实际应用,尤其涉及儿童人群超说明书适应证的扩展。
研究设计与样本
- 本文为综述性文章,回顾FDA批准儿童超声造影应用(静脉注射超声造影和膀胱内排泄性尿路超声造影)的背景与历程。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
For two decades, pediatric contrast US has been well accepted throughout Europe and other parts of the world outside the United States because of its high diagnostic efficacy and extremely favorable safety profile. This includes intravenous (IV) administration, contrast-enhanced US (CEUS) and the intravesical application, contrast-enhanced voiding urosonography (ceVUS). However, the breakthrough for pediatric contrast US in the United States did not come until 2016, when the U.S. Food and Drug Administration (FDA) approved the first pediatric indication for a US contrast agent. This initial approval covered the use of Lumason (Bracco Diagnostics, Monroe Township, NJ) for the evaluation of focal liver lesions via IV administration in children. A second pediatric indication followed shortly thereafter, when the FDA extended the use of Lumason for assessing known or suspected vesicoureteral reflux via intravesical application in children. Both initial pediatric approvals were granted without prospective pediatric clinical trials, based instead on published literature describing favorable safety and efficacy in children. Three years later, in 2019, the FDA approved Lumason for pediatric echocardiography following a clinical trial involving a total of 12 subjects at 2 sites. The story of how we achieved these FDA approvals spans more than a decade and involves the extraordinary dedication of two professional societies, namely the International Contrast Ultrasound Society (ICUS) and the Society for Pediatric Radiology (SPR). Credit also must be given to the FDA staff for their commitment to the welfare of children and their openness to compelling evidence that contrast US is a safe, reliable, radiation-free imaging option for our pediatric patients. Understanding the history of this approval process will impact the practical application of US contrast agents, particularly when expanding off-label indications in the pediatric population. This article describes the background of the FDA's approval of pediatric contrast US applications to better illuminate the potential pathways to approvals of future indications.
引用
- Darge K, Back SJ, Bulas DI, et al. Pediatric contrast-enhanced ultrasound: shedding light on the pursuit of approval in the United States. Pediatr Radiol. 2021. PMID: 34117520. doi:10.1007/s00247-021-05102-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。